EyeWorld

2 weeks ago | eyeworld.org | Susan Steury

Atia Vision received approval from the FDA to begin a feasibility clinical study with its OmniVu Lens System. According to the company, this dual-optic lens is designed to offer a more natural, accommodative range of vision. The lens consists of a fluid-filled, shape-changing base for focusing power and a front optic that gives the patient their needed optical power.

3 weeks ago | eyeworld.org | Susan Steury

Viridian Therapeutics announced that it received a Breakthrough Therapy designation from the FDA for veligrotug, a drug candidate for treatment of thyroid eye disease (TED). According to the company’s press release, this designation was granted based on the drug’s “consistent and robust improvement and resolution of diplopia in chronic TED, and [its] rapid onset of proptosis response.” The company completed two Phase 3 clinical trials that comprise the largest pivotal program for TED to date.

4 weeks ago | eyeworld.org | Susan Steury

Isarna Therapeutics announced positive Phase 2 results from its trial evaluating ISTH0036 for treatment of wet AMD and DME, including its potential to address retinal fibrosis. According to the company’s press release, ISTH0036 via intravitreal injection every 8 weeks achieved a stable or improved BCVA and meaningful anatomical retina improvements. The company reported that all patient groups saw a reduction in central retinal thickness.

1 month ago | eyeworld.org | Susan Steury

iSTAR Medical announced positive 5-year data from its extension trial from the initial EU clinical trials evaluating long-term safety and efficacy of MINIject. According to the company’s press release, this supraciliary MIGS implant was found to result in a sustained and significant 38% IOP reduction at 5 years. Of the 47 patients that completed the 5-year follow-up, 83% achieved a more than 20% reduction in IOP from baseline, and 80% had an IOP of 18 mm Hg or less at 5 years.